5 questions answered from cited research · Plain language
Yes, changes in immune cells like Kupffer cells and the broader microbiota directly worsen liver transplant outcomes by driving inflammation and tissue damage during ischemia-reperfusion injury.
Read the full answer →Synthetic inhibitors treat ischemia-reperfusion injury by blocking specific cell death pathways like ferroptosis and PANoptosis, suppressing harmful inflammation via the NLRP3 inflammasome, and neutralizing damaging molecules like platelet-activating factor or excess enzymes.
Read the full answer →Natural compounds like oridonin show promise against ischemia-reperfusion injury by suppressing inflammation and targeting specific cell death pathways, though more clinical research is needed.
Read the full answer →Yes, preclinical studies show trimetazidine reduces ischemia-reperfusion injury in organs like the heart and liver, but human trials are limited.
Read the full answer →Yes, animal studies show metformin can protect the heart from ischemia-reperfusion injury by reducing cell death, oxidative stress, and inflammation.
Read the full answer →